Effect of different doses of progestin on uterine leiomyomas in postmenopausal women

Stefano Palomba, Teresa Sena, Michele Morelli, Roberto Noia, Fulvio Zullo, Pasquale Mastrantonio

Research output: Contribution to journalArticle

Abstract

Objective(s): To evaluate the effects of two doses of medroxyprogesterone acetate (MPA) on uterine leiomyoma sizes and on uterine bleeding pattern in postmenopausal women treated with oral hormone replacement therapy (HRT). Study design: Thirty natural postmenopausal women affected by uterine leiomyomas were enrolled and treated with oral micronized estradiol (E2) at dose of 2mg per day, and randomized to receive in association MPA at dose of 2.5mg daily (group A) or of 5mg daily (group B). At the beginning of the study and after 1 year of treatment, uterine leiomyomata dimensions were measured using transvaginal ultrasonography (TV-USG). The subjects were instructed to note on a daily dairy the number and severity of abnormal uterine bleeding (AUB) episodes. Results: After 1 year of therapy, a significant changes in mean uterine leiomyomas size was observed in the group treated with higher dose of MPA. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women with uterine leiomyomas, it is necessary to use the minimal efficacious dose of progestin during HRT because of a higher risk to increase the tumors dimensions.

Original languageEnglish
Pages (from-to)199-201
Number of pages3
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume102
Issue number2
DOIs
Publication statusPublished - May 10 2002

Fingerprint

Leiomyoma
Progestins
Medroxyprogesterone Acetate
Uterine Hemorrhage
Hormone Replacement Therapy
Estradiol
Ultrasonography
Therapeutics
Neoplasms

Keywords

  • Fibroid
  • Hormonal replacement therapy
  • HRT
  • Leiomyomas
  • Postmenopause
  • Sex hormones

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. / Palomba, Stefano; Sena, Teresa; Morelli, Michele; Noia, Roberto; Zullo, Fulvio; Mastrantonio, Pasquale.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 102, No. 2, 10.05.2002, p. 199-201.

Research output: Contribution to journalArticle

Palomba, Stefano ; Sena, Teresa ; Morelli, Michele ; Noia, Roberto ; Zullo, Fulvio ; Mastrantonio, Pasquale. / Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. In: European Journal of Obstetrics and Gynecology and Reproductive Biology. 2002 ; Vol. 102, No. 2. pp. 199-201.
@article{74efc82c8ba649cb81f3b7f585f63d45,
title = "Effect of different doses of progestin on uterine leiomyomas in postmenopausal women",
abstract = "Objective(s): To evaluate the effects of two doses of medroxyprogesterone acetate (MPA) on uterine leiomyoma sizes and on uterine bleeding pattern in postmenopausal women treated with oral hormone replacement therapy (HRT). Study design: Thirty natural postmenopausal women affected by uterine leiomyomas were enrolled and treated with oral micronized estradiol (E2) at dose of 2mg per day, and randomized to receive in association MPA at dose of 2.5mg daily (group A) or of 5mg daily (group B). At the beginning of the study and after 1 year of treatment, uterine leiomyomata dimensions were measured using transvaginal ultrasonography (TV-USG). The subjects were instructed to note on a daily dairy the number and severity of abnormal uterine bleeding (AUB) episodes. Results: After 1 year of therapy, a significant changes in mean uterine leiomyomas size was observed in the group treated with higher dose of MPA. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women with uterine leiomyomas, it is necessary to use the minimal efficacious dose of progestin during HRT because of a higher risk to increase the tumors dimensions.",
keywords = "Fibroid, Hormonal replacement therapy, HRT, Leiomyomas, Postmenopause, Sex hormones",
author = "Stefano Palomba and Teresa Sena and Michele Morelli and Roberto Noia and Fulvio Zullo and Pasquale Mastrantonio",
year = "2002",
month = "5",
day = "10",
doi = "10.1016/S0301-2115(01)00588-7",
language = "English",
volume = "102",
pages = "199--201",
journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of different doses of progestin on uterine leiomyomas in postmenopausal women

AU - Palomba, Stefano

AU - Sena, Teresa

AU - Morelli, Michele

AU - Noia, Roberto

AU - Zullo, Fulvio

AU - Mastrantonio, Pasquale

PY - 2002/5/10

Y1 - 2002/5/10

N2 - Objective(s): To evaluate the effects of two doses of medroxyprogesterone acetate (MPA) on uterine leiomyoma sizes and on uterine bleeding pattern in postmenopausal women treated with oral hormone replacement therapy (HRT). Study design: Thirty natural postmenopausal women affected by uterine leiomyomas were enrolled and treated with oral micronized estradiol (E2) at dose of 2mg per day, and randomized to receive in association MPA at dose of 2.5mg daily (group A) or of 5mg daily (group B). At the beginning of the study and after 1 year of treatment, uterine leiomyomata dimensions were measured using transvaginal ultrasonography (TV-USG). The subjects were instructed to note on a daily dairy the number and severity of abnormal uterine bleeding (AUB) episodes. Results: After 1 year of therapy, a significant changes in mean uterine leiomyomas size was observed in the group treated with higher dose of MPA. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women with uterine leiomyomas, it is necessary to use the minimal efficacious dose of progestin during HRT because of a higher risk to increase the tumors dimensions.

AB - Objective(s): To evaluate the effects of two doses of medroxyprogesterone acetate (MPA) on uterine leiomyoma sizes and on uterine bleeding pattern in postmenopausal women treated with oral hormone replacement therapy (HRT). Study design: Thirty natural postmenopausal women affected by uterine leiomyomas were enrolled and treated with oral micronized estradiol (E2) at dose of 2mg per day, and randomized to receive in association MPA at dose of 2.5mg daily (group A) or of 5mg daily (group B). At the beginning of the study and after 1 year of treatment, uterine leiomyomata dimensions were measured using transvaginal ultrasonography (TV-USG). The subjects were instructed to note on a daily dairy the number and severity of abnormal uterine bleeding (AUB) episodes. Results: After 1 year of therapy, a significant changes in mean uterine leiomyomas size was observed in the group treated with higher dose of MPA. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women with uterine leiomyomas, it is necessary to use the minimal efficacious dose of progestin during HRT because of a higher risk to increase the tumors dimensions.

KW - Fibroid

KW - Hormonal replacement therapy

KW - HRT

KW - Leiomyomas

KW - Postmenopause

KW - Sex hormones

UR - http://www.scopus.com/inward/record.url?scp=0037052611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037052611&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(01)00588-7

DO - 10.1016/S0301-2115(01)00588-7

M3 - Article

C2 - 11950491

AN - SCOPUS:0037052611

VL - 102

SP - 199

EP - 201

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0028-2243

IS - 2

ER -